Skip to main content
. Author manuscript; available in PMC: 2023 Jul 27.
Published in final edited form as: Cell. 2023 Jul 5;186(15):3148–3165.e20. doi: 10.1016/j.cell.2023.06.002

Figure 1. Vaccine boosting enables CAR T-cells to elicit endogenous T-cell responses in multiple tumor models.

Figure 1.

(A) Schematic of CAR T-vax therapy. Created with BioRender.com.

(B) IFN-γ ELISPOT. Mice bearing EGFRvIII+CT-2A tumors (n=5) treated with or without CAR T + various combinations of vaccine components.

(C) Priming of endogenous CD8+ and CD4+ T-cells in EGFRvIII+CT-2A tumor-bearing mice (n=5–6) following CAR-T ± vax as measured by IFN-γ ELISPOT.

(D-G) Mice (n=5–6) bearing OVA+ B16F10 tumors received FITC/TA99 CAR T-vax.

(D) IFN-γ ELISPOT measuring OVA-specific endogenous T-cell responses.

(F) IFN-γ ELISPOT measuring endogenous T-cell responses against Trp1−/− B16F10 cells.

(F-G)Tetramer-staining showing representative flow cytometry staining (F) and mean percentages of SIINFEKL tetramer+ endogenous T cells (G).

(H) IFN-γ ELISPOT. Mice (n=4–5) bearing B16F10 tumors were treated with vax only, FITC-CAR T, or FITC/TA99 CAR T ± vax.

Error bars show mean ± 95% CI. ***, p<0.0001; **, p<0.01; *, p<0.05; n.s., not significant by one-way ANOVA with Tukey’s post-test.